42 related articles for article (PubMed ID: 36868994)
1. Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers.
Sun J; Hu S; Li X
Biomarkers; 2023 Sep; 28(6):477-485. PubMed ID: 37017446
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.
Ding Y; Sun C; Hu L; Xiong S; Zhai Z
Ann Hematol; 2023 Sep; 102(9):2425-2434. PubMed ID: 37382610
[TBL] [Abstract][Full Text] [Related]
3. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
Wei W; Xu B; Wang Y; Wu C; Jiang J; Wu C
Medicine (Baltimore); 2018 Jan; 97(3):e9617. PubMed ID: 29504990
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Soluble PD-L1 on Cardiovascular Outcomes in Patients with Coronary Artery Disease.
Miyazaki S; Fujisue K; Yamanaga K; Sueta D; Usuku H; Tabata N; Ishii M; Hanatani S; Hoshiyama T; Kanazawa H; Takashio S; Arima Y; Araki S; Yamamoto E; Matsushita K; Tsujita K
J Atheroscler Thromb; 2024 Apr; 31(4):355-367. PubMed ID: 37793811
[TBL] [Abstract][Full Text] [Related]
6. [Levels and Clinical Significances of sPD-1 and sPD-L1 in Peripheral Blood of Lymphoma Patients].
Liu XL; He P; Lei J; Zou LX; Peng L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1733-1738. PubMed ID: 38071053
[TBL] [Abstract][Full Text] [Related]
7. The predictive role of soluble programmed death ligand 1 in digestive system cancers.
Ruan J; Zhao Z; Qian Y; Xu R; Liao G; Kong FS
Front Oncol; 2023; 13():1170220. PubMed ID: 37519785
[TBL] [Abstract][Full Text] [Related]
8. Serum sPD-L1 levels are elevated in patients with viral diseases, bacterial sepsis or in patients with impaired renal function compared to healthy blood donors.
Loacker L; Egger A; Fux V; Bellmann-Weiler R; Weiss G; Griesmacher A; Hoermann G; Ratzinger F; Haslacher H; Schrezenmeier H; Anliker M
Clin Chem Lab Med; 2023 Nov; 61(12):2248-2255. PubMed ID: 37401452
[TBL] [Abstract][Full Text] [Related]
9. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract][Full Text] [Related]
10. Association of soluble PD-L1 and NLR combination with 1-Year mortality in patients with COVID-19.
Akhmaltdinova L; Mekhantseva I; Turgunova L; Kostinov M; Zhumadilova Z; Turmukhambetova A
Int Immunopharmacol; 2024 Mar; 129():111600. PubMed ID: 38325048
[TBL] [Abstract][Full Text] [Related]
11. Different Prognostic Role of Soluble PD-L1 in the Course of Severe and Non-Severe COVID-19.
Sabbatino F; Pagliano P; Sellitto C; Stefanelli B; Corbi G; Manzo V; De Bellis E; Liguori L; Salzano FA; Pepe S; Filippelli A; Conti V
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959277
[TBL] [Abstract][Full Text] [Related]
12. Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma.
Kuang RZ; Wang J; Wang YC; Tang XP
Clinics (Sao Paulo); 2024 May; 79():100376. PubMed ID: 38733690
[TBL] [Abstract][Full Text] [Related]
13. Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics.
Alrehaili AA; Gharib AF; Almalki A; Alghamdi A; Hawsawi NM; Bakhuraysah MM; Alhuthali HM; Etewa RL; Elsawy WH
Cureus; 2023 Aug; 15(8):e44338. PubMed ID: 37779773
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer.
Molga-Magusiak M; Rzepakowska A; Żurek M; Kotuła I; Demkow U; Niemczyk K
Braz J Otorhinolaryngol; 2023; 89(3):417-424. PubMed ID: 36868994
[TBL] [Abstract][Full Text] [Related]
15. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
[TBL] [Abstract][Full Text] [Related]
17. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
